 |
|
Direct Switch from Tiotropium to Indacaterol/Glycopyrronium in Chronic Obstructive Pulmonary Disease Patients in Korea
Sang Haak Lee, Chin Kook Rhee, Kwangha Yoo, Jeong Woong Park, Suk Joong Yong, Jusang Kim, Taehoon Lee, Seong Yong Lim, Ji-Hyun Lee, Hye Yun Park, Minyoung Moon, Ki-Suck Jung
Tuberc Respir Dis. 2021;84(2):96-104. Published online 2020 Dec 22 DOI: https://doi.org/10.4046/trd.2020.0109
|
|
Citations to this article as recorded by
 Revisión narrativa de la terapia inhalatoria en la EPOC
M. Villar MartÃnez, E. Calvo Manuel, A.L. Aguilar-Shea
Medicina de Familia. SEMERGEN.2024; 50(7): 102284. CrossRef Comparing Costs and Healthcare Resource Utilization (HCRU) Using LAMA versus LABA/ICS at Treatment Initiation for COPD: Findings from CITRUS (Comparing the Incidence of Tiotropium and ICS/LABA in Real-World Use in South Korea) Study
Kwang Yong Choi, Hwan Il Kim, Chin Rhee, Kwang Ha Yoo, Yong Bum Park, Youlim Kim, So Eun Lee, Jung-Ae Kim, Yong Il Hwang
International Journal of Chronic Obstructive Pulmonary Disease.2024; Volume 19: 1661. CrossRef Risk of Tuberculosis Caused by Fluticasone Propionate versus Budesonide in Chronic Obstructive Pulmonary Disease: A Nationwide Population-Based Study
Iseul Yu, Sunmin Park, Se Hwa Hong, Min-Seok Chang, Seok Jeong Lee, Suk Joong Yong, Won-Yeon Lee, Sang-Ha Kim, Ji-Ho Lee
Journal of Personalized Medicine.2022; 12(7): 1189. CrossRef Pharmacotherapy of LAMA/LABA inhaled therapy combinations for chronic obstructive pulmonary disease: a clinical overview
Maria Gabriella Matera, Barbara Rinaldi, Carmela Belardo, Mario Cazzola
Expert Review of Clinical Pharmacology.2022; 15(11): 1269. CrossRef Time to Prescribe Dual instead of Mono
Joon Young Choi
Tuberculosis and Respiratory Diseases.2021; 84(3): 252. CrossRef
|